The National Health Service /NHS is preparing to provide a new drug that treats 15 different types of cancer for patients known as “Nivolumab” in a new way that saves patients’ time.
Patients with skin, bladder, esophagus, intestine, stomach, kidneys, lung, head and neck will be among those eligible to obtain this treatment according to the British Daily Mail.
From the hospital to the house
A form of Nifolomab obtained the approval of the US Food and Drug Administration earlier this year to be injected under the skin. Experts say the subcutaneous injection form of Nevolomab – which is also known as “OPDIVO QVANTIG” – will make treatment faster and easier for patients.
The injection under the skin takes less than 5 minutes, compared to about 30 minutes for venous injection. The new pharmaceutical form may eventually allow patients to receive treatment at the Oncology Doctor Clinic, or even at home. It is allowed to give these injections to most of the patient groups that were receiving the original composition given in the vein.
Approval of subcutaneous neutolomab injections depends on the results of an experiment conducted on patients with advanced kidney cancer that compared the two types of Nevolomab. The experiment showed that both types of medicine have a similar pharmaceutical movement, that is, how to absorb, analyze and remove the drug in the body. Nifolomab was under the skin safe and effective as venous nevolomab.
Miracle medicine
Nifolomab works by linking and blocking a protein called “PD -1” (PD -1) on the surface of some cancer cells. This allows the immune system to attack cancer cells. Nevolomab is a type of immunotherapy called the immune checkpoint inhibitor. The inspection points inhibitors work by preventing the receptors used by cancer cells from sending signals that the immune cells delude them are healthy cells. And when the signal is banned, the immune cells are more able to distinguish between the cancerous cell and the sound cell and launch an attack.
Nifolomab can be used alone or with other drugs to treat hodgekin lymphocytosis in adults who have returned to cancer or their condition aggravated, in some cases of colon cancer, esophageal cancer and a number of cancer related to the digestive system, liver cancer and skin cancer.
James Richardson, clinical pharmacist and national consultant for cancer drugs from the United Kingdom, said: “I am pleased that patients with the national health service in the United Kingdom will be able to take advantage of this effective and fastest treatment treatment, which can be used to treat different types of cancer, including skin cancer and solid tumors that arise in the kidneys,” said James Richardson, Clinical Pharmacist and National Cancer Cancer Consultant from the United Kingdom.